Doctors turn to MRI to improve prostate cancer screening accuracy

Key Points:

• Prostate cancer is the most commonly diagnosed cancer in U.S. men, with over 333,000 new cases annually, but it has a very high 5-year survival rate of about 99% and only 4% mortality, partly due to overdiagnosis from PSA testing and systematic biopsies.
• Systematic prostate biopsies, the traditional standard, often detect low-grade cancers that are clinically insignificant and do not require treatment, yet about half of such cases in the U.S. still receive unnecessary treatment.
• Pre-biopsy MRI scans, standard in Europe, Canada, Australia, and the U.K., can reduce unnecessary biopsies and overdiagnosis by identifying lesions more accurately, but their adoption in the U.S. remains low at about one-third of cases due to factors like physician training gaps and financial incentives.
• There is ongoing debate among experts about the best biopsy approach: some advocate for MRI-targeted biopsies alone to reduce overdiagnosis, while others support combining targeted and systematic biopsies to avoid missing clinically significant cancers that MRIs may not detect.
• Experts agree that pre-biopsy MRI should be standard practice, but disparities in access and variability in MRI quality and interpretation in the U.S. hinder widespread implementation, leading to continued reliance on systematic biopsies and potential overtreatment.